Zerr Inga, Bähr Mathias
Department of Neurology, University Medicine Göttingen, Göttingen, Germany.
J Neurochem. 2016 Oct;139(1):9-10. doi: 10.1111/jnc.13762. Epub 2016 Sep 21.
Alterations of the cerebrospinal fluid (CSF) composition are useful clinical diagnostic tools as well as a source of candidates for new biomarkers of neurodegenerative disorders. This Editorial highlights a study by Rodrigues and colleagues in which the authors try to establish Tau as a new biomarker for Huntington´s disease (HD). The study confirmed in two independent, age-controlled patient populations at various disease stages, asymptomatic mutation carriers and healthy controls, that CSF total Tau concentrations in HD gene mutation carriers are increased compared with healthy controls. This is a strong evidence that CSF total Tau concentration is associated with phenotypic variability in HD. Read the highlighted article 'Cerebrospinal fluid total tau concentration predicts clinical phenotype in Huntington's disease' on page 22.
脑脊液（CSF）成分的改变是有用的临床诊断工具，也是神经退行性疾病新生物标志物候选物的来源。本社论重点介绍了罗德里格斯及其同事的一项研究，作者试图将 Tau 蛋白确立为亨廷顿舞蹈病（HD）的一种新生物标志物。该研究在两个独立的、年龄匹配的处于不同疾病阶段的患者群体、无症状突变携带者和健康对照中得到证实，即 HD 基因突变携带者的脑脊液总 Tau 蛋白浓度高于健康对照。这有力地证明了脑脊液总 Tau 蛋白浓度与 HD 的表型变异性相关。请阅读第 22 页的重点文章《脑脊液总 Tau 蛋白浓度可预测亨廷顿舞蹈病的临床表型》。
